(i) At EOS T2DM subjects treated with Triple Therapy had less hepatic steatosis and fibrosis versus Conventional Therapy; (ii) severity of hepatic steatosis and fibrosis both were strongly and inversely correlated with insulin resistance; (iii) changes in liver fibrosis scores (APRI, NFS, FIB-4, AST/ALT ratio) have limited value in predicting response to therapy (Diabetes, Obesity and Metabolism)
Diabetes News
Tag: pioglitazone
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
With appropriate prescription and titration, pioglitazone remains a useful tool in the arsenal of the clinical diabetologist (Cardiovascular Diabetology)
Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors
Pioglitazone use decreased the risk of new-onset ischemic stroke in Asian patients with type 2 DM and CV risk factors (Cardiovascular Diabetology)
Diabetes medications with cardiovascular protection as we enter a new decade
Can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives? (ABCD)
IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018
This study illustrated difficulties in deriving a meaningful global prevalence rate for DR and DME due to the lack of uniformity in defining the study populations, methodological differences, retinal image capture and grading criteria. Therefore, international consensus is required using a minimal data set for future studies (Diabetes Research and Clinical Practice)
Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study
This analysis suggests that pioglitazone is associated with a decrease in both cardiovascular and non-cardiovascular mortality. Results should be interpreted with caution due to the potential for residual confounding in this exploratory analysis. Further studies, specifically designed to test the association between pioglitazone use and patient-focused outcomes, are suggested (BMJ)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
In this long-term, pragmatic trial, incidence of cardiovascular events was similar with sulfonylureas (mostly glimepiride and gliclazide) and pioglitazone as add-on treatments to metformin. Both of these widely available and affordable treatments are suitable options with respect to efficacy and adverse events, although pioglitazone was associated with fewer hypoglycaemia events (The Lancet Diabetes & Endocrinology)
Effects of Pioglitazone on the Incidence of Dementia in Patients with Diabetes
Pioglitazone is a time- and dose-dependent protective factor against dementia in patients with diabetes. The risk of dementia is lower in long-term and high-dose pioglitazone users than in never users of pioglitazone (Journal of Diabetes and Its Complications)
Evaluation of exposure to pioglitazone and risk of prostate cancer: a nested case–control study
In this real-world, nested matched case–control study, exposure to pioglitazone was not associated with increased risk of prostate cancer (BMJ Open, Diabetes Research & Care)
Pioglitazone (Actos) and Bladder Cancer: Legal System Triumphs Over the Evidence
To limit their legal costs, the pharmaceutical company has established a 2.4 billion dollar settlement pool. So much for evidence-based medicine (Journal of Diabetes and Its Complications)
Pioglitazone use and risk of bladder cancer: population based cohort study
The results of this large population based study indicate that pioglitazone is associated with an increased risk of bladder cancer. The absence of an association with rosiglitazone suggests that the increased risk is drug specific and not a class effect (BMJ)
Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor
Herein, we provide an overview of the potential benefits of combined pioglitazone/empagliflozin therapy to prevent cardiovascular events in patients with type 2 diabetes mellitus (Diabetes, Obesity and Metabolism)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
In this trial involving patients without diabetes who had insulin resistance along with a recent history of ischemic stroke or TIA, the risk of stroke or myocardial infarction was lower among patients who received pioglitazone than among those who received placebo (NEJM)
Combined Intervention With Pioglitazone and n-3 Fatty Acids in Metformin-treated Type 2 Diabetic Patients
Besides preventing a modest negative effect of n-3 fatty acids on glycemic control, the combination of pioglitazone and EPA + DHA can be used to improve lipid metabolism in T2D patients on stable metformin therapy (Medscape) – Registration required
Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME
The optimal combination may be metformin, pioglitazone and empagliflozin (British Journal of Diabetes & Vascular Disease)
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Pioglitazone use was not associated with a statistically significant increased risk of bladder cancer, although an increased risk, as previously observed, could not be excluded (JAMA)
Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease
This observational study indicated a protective association of pioglitazone with cardiovascular disease and death in type 2 diabetic subjects without established vascular disease, particularly those with nephropathy (Diabetes Research and Clinical Practice)
Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population
We conclude that in patients with uncontrolled type 2 DM, continuing pioglitazone while concurrently starting bedtime insulin within a 13-month period led to a significant decrease in both HbA1c and FPG levels compared with those who did not receive pioglitazone; however weight increased during this period (Journal of Diabetes and Its Complications)
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
The cumulative use of pioglitazone or rosiglitazone was not associated with the incidence of bladder cancer in this large, pooled multipopulation analysis (Diabetologia)
Glycosmedia is also available as an App: